China mRNA specialist Stemirna gets $200m in funding
Stemirna Therapeutics, which claims to be the first biotech company to bring an mRNA therapeutics and nanomedicine platform to China, has raised $200 million in funding.
The round was led by China Merchants Health, Sequoia Capital China, Greenwoods Asset Management, and WuXi AppTec. Additional contributions came from the likes of OrbiMed, Advantech Capital, China Reform...
More on Greater China
Latest News
Japan's Heartseed raises $14m Series D
Heartseed, a Tokyo-based biotech start-up specializing in treatments that use cardiac muscle cells to initiate the remuscularization of patients who have suffered heart failure, has raised JPY 2bn (USD 14.3m) in Series D funding.
Shenzhen Capital backs Chinese titanium metal producer
Shenzhen Capital Group has participated in a CNY 2.27bn (USD 321m) funding round for Yunnan National Titanium Metal, a subsidiary of Shenzhen-listed chemicals producer LB Group.
Indonesia e-commerce player Evermos gets $39m Series C
The International Finance Corporation (IFC) has led a USD 39m Series C round for Evermos, an Indonesian social commerce platform that positions itself as an impact play.
Singapore's Qualgro seeks $150m for Fund III
Qualgro Partners, a Singapore-headquartered venture capital firm, is looking to raise USD 150m for its third fund.